Tags:BioTechDevelopmentFinTechInvestmentPaymentScience
Vaxcyte (formerly SutroVax) is developing best-in-class conjugate vaccines and complex antigen-based vaccines for infectious diseases. The company's lead programme is a broad-spectrum pneumococcal conjugate vaccine currently in clinical trials. Vaxcyte has an exclusive license to Sutro Biopharma’s Xpress CF™ platforms for cell free protein synthesis and site-specific conjugation.
Location: United States, California, Foster City

Investors 5

Mentions in press and media 8

DateTitleDescriptionCategoryAuthorSource
13.01.2022Vaxcyte An...SAN CARLOS, Calif., Jan. 13, 2...--marketscre...
13.01.2022Vaxcyte An...SAN CARLOS, Calif., Jan. 13, 2...--globenewsw...
13.01.2022Vaxcyte An...SAN CARLOS, Calif., Jan. 13, 2...--marketscre...
25.03.2021Moncef Sla...Moncef Slaoui, the former chie...--businessin...
25.03.2021Moncef Sla...Moncef Slaoui, the former chie...--businessin...
23.09.2020Healthcare...What You Should Know: – Healt...-Fred Penni...hitconsult...
23.09.2020Longitude ...- Longitude Venture Partners I...--marketscre...
-GSK fires ...Moncef Slaoui was fired as Gal...PoliticsDan Mangancnbc.com/2...